8-K current report · filed Aug 4, 2026

Strata Critical Medical, Inc. (SRTA) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02SRTA overview

Short answer

Strata Critical Medical, Inc. (SRTA) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 fiscal 2026 financial results for the quarter ended June 30, 2026 announced on August 4, 2026.

Strata Critical Medical, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 fiscal 2026 financial results for the quarter ended June 30, 2026 announced on August 4, 2026
  • Detailed results and management commentary available in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $72.5M, up 60.7% YoY, with Clinical revenue $24.3M and organic Clinical growth 15.1% sequentially
  • Adjusted EBITDA $7.9M, margin 10.9%, up from $2.5M and 5.5% YoY, signaling improved operating leverage
  • GAAP net loss $(10.5)M, driven partly by $5.0M accelerated trademark amortization and $5.5M non-cash liability revaluation
  • Three Clinical acquisitions added more than $6M projected annualized Adjusted EBITDA, expanding perfusion and transplant recovery capabilities
  • 2026 guidance raised: revenue $285-295M and Adjusted EBITDA $33-35M, while cash ended Q2 at $22.8M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Strata Critical Medical, Inc. 8-K filings

Get the next SRTA 8-K as it lands

Follow SRTA for push alerts, or ask the research agent what this filing means.